For fifty years, glyphosate-based weed killers such as Roundup have been sprayed across New Zealand’s farms, vineyards, parks, roadsides, and back gardens.
In that time, no government agency has ever conducted a full, independent risk assessment of these products as they’re actually sold and used.
So here’s a question for you: if you developed an illness that a growing body of scientific research has linked to glyphosate exposure, where would you turn? Would New Zealand’s accident compensation system even have a place for you?
You are not the victim of an “accident.” You are simply sick — and under the Accident Compensation Scheme, that distinction can mean the difference between full support and none at all.
Is that really where the line should sit?
We came across a 2008 paper by Maria Hook — now an Associate Professor of Law at the University of Otago — published in the Victoria University of Wellington Law Review, that puts a name to this problem: “man-made disease.”
Hook isn’t writing about pesticides — her paper is a general critique of ACC’s founding logic. But the moment you read it, the obvious question is: doesn’t this describe glyphosate almost exactly?
ACC’s Accident-vs-Sickness Divide
New Zealand’s Accident Compensation Scheme, set up in 1974, replaced the right to sue for personal injury with a no-fault compensation system.
It was built on a simple line: accidents are covered, sickness is not. Hook’s paper argues that this line was arbitrary from the start, and that it becomes indefensible once a disease is caused by human activity rather than by chance biology.
Her point is worth thinking about. A person who develops cancer with no identifiable external cause is just as incapacitated, and just as in need of support, as someone injured in a car accident. Yet only one of them qualifies for ACC cover — not because the accident victim deserves it more, but simply because of where ACC drew its line in 1974: accidents in, sickness out.
That line gets harder to defend once you introduce a third category: illness that may have an identifiable external cause — asbestos, industrial chemicals, workplace toxins — but unfolds over years rather than seconds. This kind of illness isn’t “sick” in the way the scheme imagines sickness (bad luck, biology). It was arguably done to the person, in the same sense an accident is done to someone, just playing out slower.
Hook’s argument: ACC’s own stated logic — that the cause of incapacity shouldn’t matter, only the incapacity itself — should already extend cover to this category, without opening the door to covering all sickness whatsoever.
Her worked example is asbestosis. A person who never worked with asbestos, but who lived near a source of exposure, gets asbestosis. Under ACC, they may get little or nothing, because they can’t point to a discrete “accident.”
A tradesperson who breathes in the same substance on the job might fare differently, depending on how their case is classified. Hook calls this exact unevenness the “lottery” ACC was designed to replace.
Why should chemical exposure keep landing people back in that lottery?
Where Glyphosate Fits the “Man-Made Disease” Pattern
Glyphosate arguably fits the kind of “man-made disease” Hook was describing: a chronic illness potentially arising from long-term exposure to a manufactured chemical, where any harm develops gradually rather than through a single traumatic event.
Before going any further, it’s worth acknowledging that the underlying science remains contested. We’ve covered the IARC classification and why other Group 2A hazards have been treated differently in detail elsewhere.
In short: the WHO’s International Agency for Research on Cancer classified glyphosate as a probable human carcinogen. Other bodies — the US EPA, the European Food Safety Authority, Australia’s pesticide regulator, and New Zealand’s own EPA — have concluded that approved uses do not pose a meaningful cancer risk to users or consumers.
A toxicology review commissioned by the New Zealand EPA concluded glyphosate is unlikely to be carcinogenic and recommended against classifying it as a mutagen or carcinogen under the HSNO Act.
So why doesn’t that settle things?
Groups challenging that conclusion, including Greenpeace Aotearoa, point out that many regulators rely heavily on unpublished industry toxicology data, while IARC’s assessments are built only on evidence available for independent scrutiny — and note that tens of thousands of US lawsuits against Roundup’s manufacturer are still working their way through the courts.
And here’s where the discussion becomes particularly important:
New Zealand has never undertaken a full, independent reassessment of glyphosate-based formulations such as Roundup as complete products.
Not the formulated products people actually buy off the shelf and spray in their own backyards — just glyphosate, the raw active ingredient, considered in isolation.
That distinction matters enormously. Roundup and similar products aren’t pure glyphosate; they’re glyphosate mixed with “co-formulants” designed to help it stick to plants and penetrate their cells, and some of those co-formulants are known to be more toxic than glyphosate itself, and can make glyphosate more toxic too.
One of them, POEA, has been banned from use in glyphosate formulations in several jurisdictions because of toxicity concerns, yet remains legally available in New Zealand — the EPA has been sitting on a promised review of POEA since 2022, with no timeline given.
The Environmental Law Initiative took the EPA to the High Court over its 2024 refusal to reassess glyphosate, specifically because the EPA’s decision looked only at glyphosate on its own and ignored the formulated products — and the co-formulants inside them — that people are actually exposed to.
The High Court ruled in October 2025 that the EPA had acted lawfully and that ELI had not established a reviewable error; ELI withdrew its Court of Appeal challenge in May 2026. The EPA has said it will keep watching international research and reassess if new information emerges, but has set no timeline for doing so.
So ask yourself: if the formulations people actually buy and spray have never undergone a full independent reassessment as complete products, what exactly has been approved all these years?
And if the regulatory question is still this open, shouldn’t the compensation question at least be asked?
The Case for ACC Reform
This is where Hook’s framework gets interesting.
What if the debate didn’t have to hinge on proving, case by case, that glyphosate caused one particular person’s illness — the kind of proof that’s notoriously hard to pin down for a disease that develops slowly, from low-level exposure, over years?
What if the argument were structural instead: that ACC should recognise “man-made disease” as a category of cover, so that people who develop illness from identifiable chemical exposure — glyphosate among others — aren’t left to navigate an accident-vs-sickness distinction that was never designed with chemical exposure in mind?
Framed that way, this isn’t a fight about whether Roundup causes cancer. It’s a fight about whether the compensation system is even asking the right question.
Hook’s paper, decades-old asbestosis case law, and the way other countries’ compensation schemes already handle occupational and environmental disease all point the same direction: recognising harm caused by identifiable, man-made exposure isn’t some radical departure from how these systems work — it’s arguably how ACC’s own “cause shouldn’t matter” logic was supposed to work all along.
Denmark’s Cancer Compensation Precedent
There’s a real-world precedent for exactly this, and it didn’t take decades.
In December 2007, the WHO’s cancer agency, IARC, classified night shift work involving circadian disruption as Group 2A — “probably carcinogenic to humans,” the same tier glyphosate would be placed in seven years later.
Denmark acted before scientific certainty had been reached. Within about a year, its National Board of Industrial Injuries began compensating women who developed breast cancer after decades of weekly night shifts, paid through their employers’ industrial injuries insurance — around 40 women, many of them flight attendants. The board was explicit that the IARC classification was the trigger.
Other countries followed in slower, quieter ways: shift-work fatigue is now treated as a hazard employers must actively manage under ISO 45001, the international occupational health and safety standard.
That’s the model Hook’s framework points toward: a government looking at a hazard classification, an identifiable human-made cause — an employer’s roster, in Denmark’s case; a chemical formulation, in glyphosate’s — and deciding that the people harmed by it shouldn’t have to win an individual scientific argument before they can be supported.
Denmark’s scheme still required strict qualifying criteria — it wasn’t a blank cheque — but it shows a “man-made disease” category isn’t a hypothetical. It already exists, for one Group 2A hazard.
The question worth asking is why the same logic hasn’t been extended to another.
Why the Regulatory and Compensation Gaps Are Linked
And it reframes the whole issue. Instead of one person fighting to prove their illness came from a chemical they were sprayed with years ago, the question becomes a public one: does New Zealand’s compensation system treat chemical exposure as the man-made harm it is, or does it quietly file it under “bad luck,” alongside diseases nobody caused at all?
That’s a question worth putting to ACC and the Ministry of Justice directly — not as a demand that the carcinogenicity debate be settled first, but as a demand that the system stop assuming it doesn’t need to have an answer.
It’s also a question the Environmental Law Initiative and Greenpeace Aotearoa are already circling from the regulatory side, in their push to get glyphosate and its co-formulants properly reassessed.
The compensation question and the regulatory question are, in the end, two halves of the same gap: nobody has fully assessed what’s actually being sprayed, and nobody has fully worked out what happens to the people it’s sprayed on.
Which leaves us back where we started.
If the formulations people actually buy and spray have never undergone a full, independent reassessment as complete products — and if the compensation system was never built with this kind of harm in mind — how many people have already fallen through that gap, simply because their illness didn’t arrive as an accident?
Key sources referenced in this article:
- Maria Hook — “New Zealand’s Accident Compensation Scheme and Man-Made Disease,” VUW Law Review, 2008 — the legal framework this article builds on
- Environmental Law Initiative — Challenging the EPA’s regulatory failure on glyphosate — case history and concerns about glyphosate co-formulants including POEA.
- Community Scoop — EPA welcomes withdrawal of appeal, May 2026 — outcome of ELI’s High Court challenge
- AgroPages — New Zealand EPA-commissioned glyphosate carcinogenicity review — toxicology review concluding glyphosate is unlikely to be carcinogenic
- Greenpeace Aotearoa — submission on glyphosate MRLs — critique of industry-reliant regulatory data and Roundup litigation figures
- MPI — Glyphosate in food — official New Zealand regulatory position and MRL guidance
- Catharine Paddock — Danish Night Shift Workers Get Compensation For Cancer, Medical News Today, 2009 — the Denmark IARC-triggered compensation precedent
- HSE Blog — Shift Work Safety and ISO 45001 — international standard treatment of shift-work fatigue as a manageable hazard
- NMGNZ — Glyphosate’s IARC Cancer Rating: Same Class, No NZ Action — our related coverage of the IARC classification
Image Source & Attribution
The feature image on this page is a screenshot of the Accident Compensation Corporation (ACC) homepage, taken on 06 July 2026. The screenshot was resized and refined for publication using Canva and is used here for editorial commentary on ACC policy discussed in this article.
